Methods and compositions of cytotoxic t cell depletion
AssigneesCrispr Therapeutics AG, Bayer HealthCare LLC
InventorBasha STANKOVICH
Life of this patent
Estimating the term…
Abstract
The present application relates to compositions and methods for controlled cytotoxic T cell depletion, such as for the treatment of various diseases and conditions associated with cytotoxic T cells. The application provides engineered T cells comprising inter alia nucleic acids encoding an anti-cytotoxic T lymphocyte (CTL) protein capable of conferring to the engineered T cell cytotoxicity towards a CTL. The anti-CTL protein may comprise an extracellular BETA2-microglobulin domain.
Claims144
An engineered T cell comprising
- a) an endogenous T cell receptor alpha (TRA) gene modified to encode a non-functional T cell receptor alpha constant (TRAC) domain;
- and
- b) nucleic acid encoding an anti-cytotoxic T lymphocyte (CTL) protein capable of conferring to the engineered T cell cytotoxicity towards a CTL that is reactive towards the engineered T cell.
A guide RNA (gRNA) comprising a sequence that is complementary to a sequence in an endogenous TRA gene within or near a region encoding the TRAC domain.
A guide RNA (gRNA) comprising a sequence that is complementary to a sequence within or near an endogenous IL2RG gene.
A vector comprising the nucleic acid sequence of any one of SEQ ID NOs:
- 19-40, or a variant thereof having at least 85% homology to any one of SEQ ID NOs:
- 19-40.
A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, a second gRNA, an RGEN or a nucleic acid encoding the RGEN, a first vector, and a second vector, wherein
- (A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 1, the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 37 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 37, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO:
- 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 40;
- (B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 2, the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 38 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 38, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO:
- 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 40;
- or
- (C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 3, the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 39 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 39, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO:
- 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 40.
A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, an RGEN or a nucleic acid encoding the RGEN, and a first vector, wherein
- (A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 1 and the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 19 or 22 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 19 or 22;
- (B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 2 and the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 20 or 23 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 20 or 23;
- or
- (C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO:
- 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 3 and the first vector comprises the polynucleotide sequence of SEQ ID NO:
- 21 or 24 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO:
- 21 or 24.
A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, an RGEN or a nucleic acid encoding the RGEN, and a first vector, wherein the first gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs:
- 4-18 and the first vector comprises the polynucleotide sequence of any one of SEQ ID NOs:
- 25-36 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs:
- 25-36.
Dependencies are inferred from the claim text.